ELVN (enliventherapeutics.com) Enterprise Value-to-Revenue Coefficient

Official company branding of Enliven Therapeutics Inc (ELVN)

Risks of failure in current clinical trials and high development costs are putting pressure on Enliven Therapeutics (ELVN) shares. The firm's EV/Sales multiple valuation on GURU.Markets exhibits a local trend, where 0.00 serves as the final level mark. Meanwhile, substantial capital ensures balance sheet stability, and innovative molecules designed to combat leukemia resistance open new therapeutic perspectives.

enliventherapeutics.com (ELVN): EV/Sales Multiple from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Enliven Therapeutics, Inc. (ELVN)

- business market valuation indicators:
- cash balance and cash flow data:
Fundamental company valuation:Enliven Therapeutics ELVN
Product sample of enliventherapeutics.com

For Enliven Therapeutics (ELVN), the Enterprise Value-to-revenue ratio serves as an indicator of the business's market value, stripped of the influence of leverage. This metric compares the total value of assets with sales volume, revealing valuation deviations from actual cash flows. The sensitivity of this indicator allows speculative noise to be separated from fundamental growth. In the context of developing targeted inhibitors, this reflects the capitalization of patent potential to overcome tumor resistance. The price action on this chart determines the fairness of the premium for the company's technological advantage.